Circulating tumor cells (CTCs) are associated with prognosis in a variety of human cancers and have been proposed as a liquid biopsy for follow-up examinations. We show that tumor suppressor and metastasis suppressor genes are epigenetically silenced in CTCs isolated from peripheral blood of breast cancer patients.
Whereas methylation of cancer-related genes plays a fundamental role in the development and progression of cancer and is a promising biomarker for early detection and prognosis estimation (16 ) , it has not been studied as yet in CTCs.
Cystatin M or E/M [encoded by cystatin E/M (CST6) 6 ] is an endogenous inhibitor of cathepsins B and L (17 ) that was first identified by differential display of mRNAs as being markedly downregulated in metastatic breast cancer (18 ) and mapped to chromosomal locus 11q13 (19 ) . DNA hypermethylation in this region impairs transcription and leads to loss of cystatin M expression in cancer (20 -23 ) . Cystatin M has generated much recent interest and is postulated to be a tumor suppressor in breast cancer (21 ) . Indeed, exogenous cystatin M expression in a breast cancer cell line resulted in significant reduction of cell proliferation, migration, Matrigel invasion, and adhesion to endothelial cells (20 ) . CST6 promoter methylation provides important prognostic information in patients with operable breast cancer (24 ) .
Breast cancer metastasis suppressor 1 (BRMS1), a known suppressor of metastasis, is a predominantly nuclear protein that differentially regulates expression of multiple genes, leading to suppression of metastasis without blocking orthotopic tumor growth (25 ) . BRMS1 is significantly downregulated in some breast tumors, especially in metastatic disease, by epigenetic silencing (26 ) . BRMS1 coordinately regulates expression of multiple metastasis-associated micro-RNAs (miRNAs) (27 ) , whereas its expression in metastatic human breast cancer cells leads to selective repression of epidermal growth factor receptor and downstream Akt signaling (28 ) .
SRY (sex-determining region Y)-box 17 (SOX17) plays a critical role in the regulation of development and stem/precursor cell function, at least partly through repression of the canonical Wnt/␤-catenin signaling pathway. SOX17 gene silencing is associated with DNA hypermethylation of a C-phosphate-G (CpG) island located in the promoter region (29 ) . It is well established that SOX17 plays a tumor suppressor role through suppression of Wnt signaling (30 ) .
The aim of our study was to investigate, for the first time, the methylation status of tumor suppressor and metastasis suppressor genes in CTCs. The CST6, BRMS1, and SOX17 tumor suppressors were selected because their epigenetic inactivation has been causally associated with cancer.
Materials and Methods

PATIENTS
We recruited 83 breast cancer patients: (a) 56 patients with operable breast cancer at least 2 weeks after removal of the primary tumor and before the initiation of adjuvant chemotherapy and (b) 27 patients with metastatic breast cancer. We enrolled 23 healthy female blood donors as a control group. Peripheral blood (20 mL in EDTA) was obtained at the middle of vein puncture after the first 5 mL of blood was discarded. All blood samples were processed within 4 h of collection as described (31, 32 ) . All individuals signed an informed consent to participate in the study, which was approved by the ethics and scientific committees of our institutions. A diagram outlining the procedure is shown in Fig. 1 .
IMMUNOMAGNETIC ISOLATION OF CTCs
After dilution of peripheral blood with 20 mL PBS (pH 7.3), we obtained peripheral blood mononuclear cells (PBMCs) by gradient density centrifugation using Ficoll-Paque™ Plus (GE Healthcare, Bio-Sciences AB) at 670g for 30 min at room temperature. The interface cells were removed, washed twice with 40 mL sterile PBS (pH 7.3, 4°C), centrifuged at 530g for 10 min, and resuspended in 1 mL PBS. Cells were dyed with Trypan blue and counted in a hemocytometer. We used immunomagnetic Ber-EP4 [anti-epithelial cell adhesion molecule (anti-EpCAM)]-coated capture beads (Dynabeads® Epithelial Enrich, Invitrogen) to enrich epithelial cells according to the manufacturer's protocol.
RNA EXTRACTION FROM CTCs
We performed total RNA isolation with Trizol (Invitrogen) and measured RNA concentrations using the Nanodrop-1000 (NanoDrop Technologies). mRNA was isolated from total RNA using the Dynabeads mRNA Purification kit (Invitrogen) as described (32 ) . cDNA synthesis was performed using the SuperScript™ First-Strand Synthesis System (Invitrogen) and the cDNA was used for KRT19 expression studies in CTCs as described (31 ) .
DNA EXTRACTION FROM CTCs
After removal of the aqueous phase of Trizol, DNA was precipitated from the interphase by adding 150 L of 100% ethanol. Samples were mixed by inversion and kept at room temperature for 2-3 min, and the DNA was sedimented by centrifugation (2000g, 5 min, 4°C) and washed twice in a solution containing 0.1 mol/L sodium citrate in 10% ethanol (500 L). In each wash, the DNA pellet was stored in the washing solution for 30 min at room temperature with periodic mixing and centrifuged (2000g, 5 min, 4°C). After these 2 washes, the DNA pellet was suspended in 1 mL of 75% ethanol, kept for 10 -20 min at room temperature with periodic mixing, and centrifuged (2000g, 5 min, 4°C). Isolated DNA was then air-dried for 15 min and dissolved in 50 L of 8 mmol/L NaOH. We determined the DNA concentration in the Nanodrop-1000.
SODIUM BISULFITE CONVERSION
We modified the DNA extracted from isolated CTCs by a sodium bisulfite (SB) reaction carried out in denatured DNA using the EZ DNA Methylation Gold Kit (Zymo) following the short program (reaction time 160 min). The converted DNA was stored at Ϫ70°C until use. In each SB reaction, distilled H 2 O (PCR grade) and MCF-7 cells (or MDA-MB-231 cells) were included as negative and positive controls, respectively.
METHYLATION-SPECIFIC PCR
All methylation-specific PCR (MSP) reactions were performed in an Eppendorf Mastercycler. MSP products were fractionated on 2% agarose gels containing 40 mmol/L Tris-acetate/1.0 mmol/L EDTA (pH 8.0). To avoid false-negative results, we amplified SBtreated DNA in 2 separate MSP reactions, 1 with a set of primers specific for methylated and 1 for unmethylated CST6 promoter sequences (24 ) . We used human placental genomic DNA (gDNA; Sigma-Aldrich) methylated in vitro with SssI methylase (NEB), after SB conversion, as a fully methylated (100%) MSP positive control; we used the same unmethylated placental gDNA, after SB conversion, as a negative MSP control. MSP primers are shown in Supplemental Table 1 , which accompanies the online version of this article at http://www.clinchem.org/content/vol57/issue8, and MSP reaction conditions for each gene are shown in detail in online Supplemental Table 2 .
STATISTICAL ANALYSIS
We performed statistical evaluation of data using SPSS (SPSS Statistics 17.0). We used the 2 test of independence (SPSS, version 17.0) for data analysis and for the evaluation of the significance of differences between groups, and Fisher exact test for the evaluation of the correlation between methylation of each gene in re- spect to the patient's characteristics and DNA methylation of each gene in respect to KRT19 gene expression.
Results
ANALYTICAL SENSITIVITY AND SPECIFICITY OF MSP ASSAYS
We extensively evaluated the analytical sensitivity and specificity of the MSP assay for CST6 promoter methylation in our previous study (24 ) . The analytical sensitivity and specificity of the MSP assays for BRMS1 and SOX17 promoter methylation have been evaluated (26, 29, 33 ) . MSP for CST6 with primers specific for the unmethylated DNA was performed for all SBconverted samples to exclude failure of PCR reaction when the PCR reaction specific for the methylated DNA sequences was negative.
DNA METHYLATION OF TUMOR SUPPRESSOR GENES IN CTCs
CST6 promoter methylation was observed in 10 of 56 (17.9%) patients with operable breast cancer and 10 of 27 (37.0%) patients with metastasis; CST6 promoter methylation was observed in 1 (4.3%) of 23 blood samples from healthy individuals using exactly the same procedure.
Interestingly, previous studies have reported differences in the methylation status of BRMS1 in primary tumors (26 ) . In this study, we found that the BRMS1 promoter was highly methylated in CTCs of breast cancer patients. BRMS1 promoter methylation was observed in 18 of 56 (32.1%) patients with operable breast cancer, 12 of 27 (44.4%) patients with metastasis, and 2 (8.7%) of 23 peripheral blood samples from healthy individuals.
The importance of epigenetic silencing of SOX17 gene was shown very recently (29, 33 ) . We observed that SOX17 promoter is highly methylated in CTCs. SOX17 promoter methylation was observed in 30 of 56 (53.6%) patients with operable breast cancer and 20 of 27 (74.1%) patients with distant metastasis. Conversely, SOX17 promoter methylation was observed in only 1 (4.3%) of 23 peripheral blood samples obtained from healthy individuals.
When we correlated the patient's characteristics with our results on DNA methylation, we found no association of DNA methylation of these genes, except for a correlation between CST6 methylation and menopausal status (P ϭ 0.03) and tumor size (P ϭ 0.05), and between BRMS1 methylation and tumor size (P ϭ 0.05) ( Table 1) . Table 2 shows the localization of metastases with respect to the methylation profile of these genes in CTCs for each individual patient.
Using 2 test analysis, we found that methylation of the promoter of each gene was different between the 3 groups: CST6, Pearson 2 8640, df 2, P ϭ 0.013; BRMS1, Pearson 2 7746, df 2, P ϭ 0.021; SOX17, Pearson 2 25604, df 2, P ϭ 0.000.
CST6, BRMS1, AND SOX17 PROMOTER METHYLATION AND KRT19
EXPRESSION IN CTCs
KRT19 has been extensively used as an epithelial marker, characteristic for the presence of CTCs (6) (7) (8) 11) . For this reason, we also studied in all these clinical samples the expression of KRT19 in the EpCAM-positive, immunomagnetically isolated CTC fraction. We found 24 samples positive for KRT19 expression of 56 early breast cancer patients studied (42.8%) and 14 of 27 (51.8%) patients with verified metastasis, whereas none of the 23 healthy individual samples was positive for KRT19 expression. Table 3 shows the results for CST6, BRMS1, and SOX17 promoter methylation in comparison to the expression of KRT19 expression in CTCs. In early breast cancer, the concordance between CST6 promoter methylation and KRT19 gene expression was 53.6% (30/56), whereas in patients with metastasis, the concordance was 40.7% (11/27) (Table 3) . The concordance between BRMS1 promoter methylation and KRT19 gene expression in early breast cancer was 46.4% (26/56), whereas in patients with overt metastasis, the concordance was 48.1% (13/27) . In early breast cancer, the concordance between SOX17 promoter methylation and KRT19 gene expression was 32.1% (18/56). We found an inverse correlation between SOX17 promoter methylation and KRT19 expression. In patients with verified metastasis, the concordance between SOX17 promoter methylation and KRT19 gene expression was 55.5% (15/27) .
A heat map for CST6, BRMS1, and SOX17 promoter methylation and KRT19 expression in the CTC fraction of each patient in all 3 groups studied is shown in Fig. 2 . Each patient had a different profile concerning DNA methylation of these genes in CTCs. In 5 of 56 (8.9%) patients with early breast cancer and 6 of 27 (22.2%) patients with verified metastasis, all 3 genes were methylated.
Discussion
Our study provides the first evidence that DNA methylation of tumor suppressor and metastasis suppressor genes exists in CTCs. We found that the promoters of the tumor suppressor genes CST6 and SOX17 and metastasis suppressor BRMS1 are methylated in CTC isolated from peripheral blood of breast cancer patients, in both groups of early disease and verified metastasis. In operable breast cancer, the percentage of DNA methylation in all 3 of these genes was lower but not significantly different from that found in the group of patients with overt metastasis, whereas for both operable and metastatic breast cancer this was significantly different from the control population.
Whole genome studies identified CST6 as among the 10 hypermethylated genes that distinguish between cancerous and normal tissues (34 ) , and its methylation was associated with epithelial-to-mesenchymal transition (35 ) . A recent functional epigenetic study identified CST6 as 1 of 8 genes that showed frequent (Ͼ30%) tumor-specific promoter region hypermethylation associated with transcriptional silencing and that its re- expression suppressed the growth of renal cell carcinoma cell lines (36 ) . Moreover, according to our recent findings, CST6 methylation is a promising biomarker for prediction of relapses and deaths in operable breast cancer (24 ) . Here we provide evidence that the CST6 promoter is methylated in CTCs. BRMS1 suppresses breast cancer metastasis in multiple experimental models by reducing solitary cell survival and inhibiting growth initiation (37 ) . Loss of BRMS1 expression has been shown to predict reduced disease-free survival in subsets of breast cancer patients (38 ) . We found that BRMS1 is methylated in CTC, a finding that is consistent with other studies that showed significant downregulation of BRMS1 in some breast tumors, especially in metastatic disease, because of epigenetic silencing (26 ) . Recent observations demonstrated that methylation of the promoter-associated CpG island in BRMS1 results in its transcriptional repression and highlighted the potential clinical relevance of this event with respect to non-small cell lung cancer tumor histology and pathological stage (39 ) .
Similarly, SOX17 plays a critical role in the regulation of development and stem/precursor cell function, at least partly through repression of Wnt pathway activity (30 ) . SOX17 has been shown to alter adult lung progenitor cell fate, decrease the expression of transforming growth factor-␤ (TGF-␤)-responsive cell cycle inhibitors, and inhibit TGF-␤1-mediated transcriptional responses in vitro, while blocking Smad3 DNA binding and transcriptional activity (40 ) . Silencing of SOX17 due to promoter hypermethylation is a frequent event and may contribute to aberrant activation of Wnt signaling in breast cancer (33 ) . Our data demonstrate that SOX17 promoter is methylated in the CTC fraction in the majority of operable (53.6%) and metastatic (74.1%) breast cancer patients.
Further molecular characterization of CTCs is important not only to confirm their malignant origin but also to identify diagnostically and therapeutically relevant targets to help stratify cancer patients for individual therapies. Molecular characterization of CTCs can expand our knowledge of basic molecular pathways of invasion, migration, and immune surveillance. The big question is how soon that knowledge will be translated into new clinical concepts for diagnosis and therapy. Toward this, our group has very recently developed a multiplexed PCR-coupled liquid bead array to detect the expression of multiple genes in CTCs (32 ) .
In this study, we aimed to molecularly characterize CTCs at the epigenetic level. Our data show that tumor suppression is severely disarmed in CTC via progressive DNA hypermethylation that leads to epigenetic silencing of key tumor suppressors and metastasis suppressors known to affect hallmark properties of tumor cells, including growth and proliferation, invasiveness, epithelial phenotype, and stemness. We have chosen to first study CST6, BRMS1, and SOX17 gene methylation in CTCs, after a very careful search in the literature, since the available material for CTC analysis is extremely low. These 3 genes, as already established through other studies in cell lines and primary tumors, each play an important role in preventing metastasis (18, 19, 25, 27, 28, 30 ) . Methylation of their promoters is highly correlated with their epigenetic silencing, development of metastasis, and poor prognosis (21, 23, 24, 26, 29 ) .
Our results also confirm the heterogeneity of CTCs, since the methylation profile was different in individual patients. Evaluation of these different profiles in respect to the clinical outcome, metastasis site, and patient characteristics will be possible only when a larger number of clinical samples with a known clinical outcome are analyzed. Interestingly, we also found highly methylated gene promoter sequences in the CTC fraction of EpCAM-positive/KRT19-negative patients. This confirms the observation that multiparametric evaluation of CTCs is of critical importance (32 ) .
Epigenetic silencing of tumor and metastasis suppressor genes in CTCs by increased DNA methylation with advanced disease provides new insights into the dynamics of metastasis. Combinatorial patterns of aberrant DNA methylation associated with the sequential silencing of key tumor suppressors is consistent with the wide heterogeneity of CTCs and may play a critical role in the evolutionary selection of increasingly aggressive CTC variants with acquired capacity for selfseeding at the primary tumor site, but also at distinct metastatic sites, thus accelerating tumor progression. Elucidating the interplay between epigenetic gene silencing and other tumorigenic processes in CTCs will be crucial to our understanding of tumor evolution and metastasis.
Our findings add a new dimension to the malignant nature and metastatic potential of CTCs. Whether the presence or absence of DNA methylation in CTCs is of prognostic, predictive, or therapeutic importance has yet to be determined. We believe that our findings should be explored in a prospective study, in respect to the clinical outcome of breast cancer patients with CST6, BRMS1, and SOX17 promoter methylation in CTCs.
